Latest National Comprehensive Cancer Network Stories
BETHESDA, Md., July 12, 2011 /PRNewswire-USNewswire/ -- According to a study released this week by UCLA's Jonsson Comprehensive Cancer Center, the overwhelming majority of patients with high-grade non-muscle invasive bladder cancer do not receive the recommended treatment and surveillance, leaving them at higher risk for bladder cancer recurrence, progression, and death. The Bladder Cancer Advocacy Network (BCAN), the first national organization dedicated to advancing bladder cancer research...
Nearly all patients with high-grade, non-invasive bladder cancer are not receiving the guideline-recommended care that would best protect them from recurrence, according to this study.
A study at UCLA's Jonsson Comprehensive Cancer Center found that nearly all patients with high-grade, non-invasive bladder cancer are not receiving the guideline-recommended care that would best protect them from recurrence, a finding that researchers characterized as alarming.
Most hospitals follow established practice guidelines for surgery involving Medicare beneficiaries with cancer, but in some cases their practice patterns diverge from the guidelines.
DALLAS and THE WOODLANDS, Texas, June 17, 2011 /PRNewswire/ -- An advanced proton therapy center for cancer treatment could be coming to North Texas. The innovative proton treatment facility would enhance regional cancer care and attract patients both nationally and internationally.
ATLANTA, June 8, 2011 /PRNewswire/ -- Elekta has collaborated with the National Comprehensive Cancer NetworkÂ® (NCCNÂ®) to integrate the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(TM)) into Elekta's MOSAIQÂ® Oncology Information System.
Texas Oncology Research Showcased at American Society of Clinical Oncologists Annual Meeting Dallas, TX (PRWEB) June 03, 2011 Twenty-two Texas Oncology physicians have contributed research findings to the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, which opened June 3.
The cost of cancer care is threatening to bankrupt our healthcare system.
PITTSBURGH, May 24, 2011 /PRNewswire/ -- D3 Oncology Solutions today announced that it will provide its Via Oncology Pathways for a six-month free trial period to enable cancer programs to align the timing of their investment with a strategy for sharing potential savings with payors and other key stakeholders.
PITTSBURGH, April 7, 2011 /PRNewswire/ -- Precision Therapeutics, Inc. announced that the launch of a new product line, BioSpeciFxÂ®, will help further the personalization of cancer treatments.
- The act of lurking; skulking about; hiding; keeping from sight.